Acadia Pharmaceuticals ACAD reported third-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate ...

More defined timelines will be given in early 2025, probably with fourth quarter results or soon thereafter. In addition, ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20241106212607/en/ Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858) 261 ...

Revenue: US$250.4m (up 18% from 3Q 2023). Net income: US$32.8m (up from US$65.2m loss in 3Q 2023). Profit margin: 13% (up from net loss in 3Q 2023). The move to profitability was primarily driven ...

(ACAD) on Wednesday reported third-quarter net income of $32.8 million, after reporting a loss in the same period a year earlier.

Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher (PRV)—although the biotech will ...

Acadia , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $250.4 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.46% ...

Acadia Realty Trust (NYSE:AKR – Free Report) by 10.0% during the 3rd quarter, Holdings Channel reports. The firm owned 21,535 ...

Acadia Realty Trust has purchased the retail site at 109 North Sixth Street in Williamsburg, Brooklyn, for $18.9 million.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.

These 10 defensive stocks supply investors with reliable earnings, and often dividends, when markets look uncertain. We sell different types of products and services to both investment ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024. “The success of Acadia’s two ...